Report applicable HCPCS J‑codes on prior authorization and claims

Include the specific HCPCS J‑codes for the hyaluronan product(s) being administered (listed in the policy as J7318, J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332) on any prior authorization request and on the claim form so the service and product are clearly identified.

• List the applicable HCPCS J‑code(s) for the injected product on the authorization request.
• Report the same HCPCS J‑code(s) on the claim when billing for the injection.

Document prior conservative therapy and product‑specific regimen for PA

When requesting authorization, document that the patient has failed conservative nonpharmacologic therapy and simple analgesics as described in product labeling, and confirm the intended product’s manufacturer‑specified injection regimen (e.g., single‑dose or 1–5 weekly injections) because schedules vary by product.

• Provide documentation of prior conservative nonpharmacologic therapies tried and insufficient response (per product inserts).
• Specify the product to be used and the planned injection schedule (single‑dose vs. multiple weekly injections) consistent with its labeling.

Confirm prior‑authorization requirements per member benefits

Verify whether prior authorization is required for the member and follow the member’s benefit administration; this policy guides medical necessity determinations but PA requirements depend on the member’s specific benefit plan and administrator.

• Check the member benefit booklet or contact member services to determine PA requirements and any benefit limits.
• Submit PA only when required by the member’s plan administration.

No step‑therapy algorithm specified in policy

No insurer step therapy algorithm is specified in this policy segment; do not assume an internal step‑therapy prior authorization pathway is required by this document alone.

• Follow plan‑specific utilization management rules if the member’s plan implements step therapy.

Follow stepwise use per product labeling (after conservative therapy failure)

Recognize that manufacturers’ labeling positions the products for use after failure of conservative nonpharmacologic therapy and simple analgesics, supporting a stepwise treatment approach per product labeling.

• Labels indicate use in knee OA patients who have failed conservative measures and simple analgesics.
• Injection frequency and number of doses differ by product (examples provided in labeling).

Policy does not state explicit step‑therapy requirements

Restatement from the policy: the document does not set an explicit step therapy requirement in this segment; check the member’s plan for any local step therapy rules.

• If the payer or product‑specific program requires step therapy, follow those external requirements.

Bill using the listed HCPCS J‑codes (J7318–J7332)

When billing for intra‑articular hyaluronan injections, report the applicable HCPCS J‑code(s) from the policy (J7318–J7332) on the claim to identify the product administered.

• Use the HCPCS J‑code that corresponds to the specific hyaluronan product and dose administered.

Document manufacturer‑prescribed indications and regimen

If relying on manufacturer prescribing information to support therapy, include documentation that the patient failed conservative nonpharmacologic therapy and simple analgesics and cite the product‑specific regimen, since labels state these criteria for knee OA use.

• Attach product labeling or document the relevant labeled indication and regimen when submitting justification.

Benefit verification required prior to service

Always verify member coverage before providing service; consult the member benefit booklet or contact customer service to determine whether the service is covered under the specific member’s plan.

• Benefit verification is required because coverage is subject to member plan limits and this policy does not apply to Medicare Advantage.

Denial risk: knee injections NMN; other joints investigational

Be aware that claims for intra‑articular hyaluronan injections of the knee are considered not medically necessary by this policy and claims for injections in other joints are considered investigational; such claims may be denied if submitted without contrary benefit provisions.

• Knee injections: policy states 'not medically necessary' and may be denied.
• All other joints: policy states 'investigational' and may be denied.

FDA joint‑limitation: only FDA‑approved for knee — non‑knee use may be non‑covered

Do not submit claims for injections in joints for which the product is not FDA‑approved without clear benefit coverage; FDA has approved IA hyaluronan for the knee only, and use in other joints may be considered non‑covered or investigational.

• If treating a non‑knee joint, document clinical rationale but expect the service to be investigational per policy and potentially non‑covered.

Historic policy: IA hyaluronan previously considered not medically necessary

Historic policy history notes that intra‑articular hyaluronan for osteoarthritis has previously been considered not medically necessary; include this context if needed for appeals or benefit discussions.

• Historic entries document the NMN stance dating back to policy history (example: effective 03/01/15).